A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...

A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...

Cohen, E. and Kubinak, N. (2025) A Rare Presentation of Cavernous Sinus Thrombosis in a Young Female. Surgical Science, 16, ...

Over a hundred sickle cell warriors and their families turned out in support for World Sickle Cell Day at West Oakland’s ...

Several other medical conditions can mimic the symptoms of low testosterone, including depression, sleep apnea, ...

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic ...

Learn more about myocardial ischemia, which is often caused by severe anemia and results in a disruption of blood flow to the ...

Anemia is a common condition and has many causes, one of which is hemolytic disease of the fetus and newborn (HDFN), a ...

New findings reveal that combining erythropoiesis-stimulating agents with ruxolitinib maintains efficacy in treating ...

This anemia tends to be more persistent and difficult to treat. The treatments for hereditary anemias, such as thalassemia or sickle cell disease, vary widely and depend on the specific condition ...

However, people with severe anemia or neuropsychiatric symptoms (like the brain fog and tingling you noted) should be treated aggressively to avoid possibly permanent nerve damage.